Provided by Tiger Fintech (Singapore) Pte. Ltd.

Catalyst Pharmaceuticals

22.76
-0.7000-2.98%
Post-market: 22.22-0.5356-2.35%19:58 EDT
Volume:2.68M
Turnover:59.56M
Market Cap:2.78B
PE:17.37
High:23.17
Open:23.17
Low:20.80
Close:23.46
Loading ...

Company Profile

Company Name:
Catalyst Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
181
Office Location:
355 Alhambra Circle,Suite 801,Coral Gables,Florida,United States
Zip Code:
33134
Fax:
- -
Introduction:
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Directors

Name
Position
Patrick J. McEnany
Chairman,President and CEO
Charles B. O'Keeffe
Lead Independent Director
David S. Tierney
Director
Donald A. Denkhaus
Director
Molly Harper
Director
Richard J. Daly
Director
Tamar Thompson
Director

Shareholders

Name
Position
Steven R. Miller
Chief Operating Officer and Chief Scientific Officer
Alicia Grande
Vice President, Treasurer and Chief Financial Officer
Brian Elsbernd
Chief Compliance Officer and Chief Legal Officer
Gary Ingenito
Chief Medical and Regulatory Officer
Jeffrey Del Carmen
Chief Commercial Officer
Patrick J. McEnany
Chairman,President and CEO
Preethi Sundaram
Chief Strategy Officer